Actively Recruiting
Research on Genomic Profiling and New Antibody Treatments for Childhood Leukemia with Focus on Precision Medicine and Long-term Benefits
Led by Chinese University of Hong Kong · Updated on 2026-02-03
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to advance treatment for childhood leukemia, the most common cancer in children. Despite improved outcomes, relapse occurs in 15-40% of cases, often leading to survival rates below 50%. Because increasing standard chemotherapy can cause severe side effects, the study focuses on developing safer, targeted therapies for high-risk patients through two main projects involving genetic analysis and novel antibody development. The first project uses whole-exome and RNA sequencing on children with various types of leukemia to analyze genetic changes and drug sensitivity in samples from blood and bone marrow. The second project develops new antibodies tested in animal models to assess their safety and effectiveness against relapsed or hard-to-treat leukemia. These approaches aim to support precision medicine tailored to each childs leukemia. Participants provide samples for genetic and drug sensitivity testing, which researchers use to identify which patients might benefit from targeted treatments. The study measures include genetic alterations, gene expression, drug sensitivity, and antibody treatment efficacy over up to one year. This research may lead to improved therapies for children with leukemia and has both immediate and long-term goals for treatment progress.
CONDITIONS
Brief Title
Advanced Translational Research on Childhood Leukemia
Research Team
K
Kathy Chan, Ph. D.
K
Kam Tong Leung, Ph. D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here